Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Altered exocrine function can drive adipose wasting in early pancreatic cancer.

Danai LV, Babic A, Rosenthal MH, Dennstedt EA, Muir A, Lien EC, Mayers JR, Tai K, Lau AN, Jones-Sali P, Prado CM, Petersen GM, Takahashi N, Sugimoto M, Yeh JJ, Lopez N, Bardeesy N, Fernandez-Del Castillo C, Liss AS, Koong AC, Bui J, Yuan C, Welch MW, Brais LK, Kulke MH, Dennis C, Clish CB, Wolpin BM, Vander Heiden MG.

Nature. 2018 Jun;558(7711):600-604. doi: 10.1038/s41586-018-0235-7. Epub 2018 Jun 20.

2.

Establishment and characterization of a novel murine model of pancreatic cancer cachexia.

Michaelis KA, Zhu X, Burfeind KG, Krasnow SM, Levasseur PR, Morgan TK, Marks DL.

J Cachexia Sarcopenia Muscle. 2017 Oct;8(5):824-838. doi: 10.1002/jcsm.12225. Epub 2017 Jul 20.

3.

Phases of Metabolic and Soft Tissue Changes in Months Preceding a Diagnosis of Pancreatic Ductal Adenocarcinoma.

Sah RP, Sharma A, Nagpal S, Patlolla SH, Sharma A, Kandlakunta H, Anani V, Angom RS, Kamboj AK, Ahmed N, Mohapatra S, Vivekanandhan S, Philbrick KA, Weston A, Takahashi N, Kirkland J, Javeed N, Matveyenko A, Levy MJ, Mukhopadhyay D, Chari ST.

Gastroenterology. 2019 May;156(6):1742-1752. doi: 10.1053/j.gastro.2019.01.039. Epub 2019 Jan 22.

PMID:
30677401
4.

Pancreatic exocrine insufficiency in LXRbeta-/- mice is associated with a reduction in aquaporin-1 expression.

Gabbi C, Kim HJ, Hultenby K, Bouton D, Toresson G, Warner M, Gustafsson JA.

Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15052-7. doi: 10.1073/pnas.0808097105. Epub 2008 Sep 19.

5.

Deficiency in hormone-sensitive lipase accelerates the development of pancreatic cancer in conditional KrasG12D mice.

Xu M, Chang HH, Jung X, Moro A, Chou CEN, King J, Hines OJ, Sinnett-Smith J, Rozengurt E, Eibl G.

BMC Cancer. 2018 Aug 7;18(1):797. doi: 10.1186/s12885-018-4713-y.

6.

Fatty pancreas: A possible risk factor for pancreatic cancer in animals and humans.

Takahashi M, Hori M, Ishigamori R, Mutoh M, Imai T, Nakagama H.

Cancer Sci. 2018 Oct;109(10):3013-3023. doi: 10.1111/cas.13766. Epub 2018 Sep 5. Review.

7.

The epigenetic regulators Bmi1 and Ring1B are differentially regulated in pancreatitis and pancreatic ductal adenocarcinoma.

Martínez-Romero C, Rooman I, Skoudy A, Guerra C, Molero X, González A, Iglesias M, Lobato T, Bosch A, Barbacid M, Real FX, Hernández-Muñoz I.

J Pathol. 2009 Oct;219(2):205-13. doi: 10.1002/path.2585.

PMID:
19585519
8.

Pancreatic Exocrine Insufficiency in Pancreatic Cancer.

Vujasinovic M, Valente R, Del Chiaro M, Permert J, Löhr JM.

Nutrients. 2017 Feb 23;9(3). pii: E183. doi: 10.3390/nu9030183. Review.

9.

Pancreatic fatty degeneration and fibrosis as predisposing factors for the development of pancreatic ductal adenocarcinoma.

Tomita Y, Azuma K, Nonaka Y, Kamada Y, Tomoeda M, Kishida M, Tanemura M, Miyoshi E.

Pancreas. 2014 Oct;43(7):1032-41. doi: 10.1097/MPA.0000000000000159.

PMID:
24991971
10.

Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42.

Henderson SE, Ding LY, Mo X, Bekaii-Saab T, Kulp SK, Chen CS, Huang PH.

Neoplasia. 2016 Dec;18(12):765-774. doi: 10.1016/j.neo.2016.10.003. Epub 2016 Nov 25.

11.

Involvement of angiotensin II type 2 receptor (AT2R) signaling in human pancreatic ductal adenocarcinoma (PDAC): a novel AT2R agonist effectively attenuates growth of PDAC grafts in mice.

Ishiguro S, Yoshimura K, Tsunedomi R, Oka M, Takao S, Inui M, Kawabata A, Wall T, Magafa V, Cordopatis P, Tzakos AG, Tamura M.

Cancer Biol Ther. 2015;16(2):307-16. doi: 10.1080/15384047.2014.1002357.

12.

Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer.

Ramsey ML, Talbert E, Ahn D, Bekaii-Saab T, Badi N, Bloomston PM, Conwell DL, Cruz-Monserrate Z, Dillhoff M, Farren MR, Hinton A, Krishna SG, Lesinski GB, Mace T, Manilchuk A, Noonan A, Pawlik TM, Rajasekera PV, Schmidt C, Guttridge D, Hart PA.

Pancreatology. 2019 Jan;19(1):80-87. doi: 10.1016/j.pan.2018.11.002. Epub 2018 Nov 10.

PMID:
30497874
13.

Pancreatic satellite cells derived galectin-1 increase the progression and less survival of pancreatic ductal adenocarcinoma.

Tang D, Zhang J, Yuan Z, Gao J, Wang S, Ye N, Li P, Gao S, Miao Y, Wang D, Jiang K.

PLoS One. 2014 Mar 4;9(3):e90476. doi: 10.1371/journal.pone.0090476. eCollection 2014.

14.

Predictive factors of endocrine and exocrine insufficiency after resection of a benign tumour of the pancreas.

Neophytou H, Wangermez M, Gand E, Carretier M, Danion J, Richer JP.

Ann Endocrinol (Paris). 2018 Apr;79(2):53-61. doi: 10.1016/j.ando.2017.10.003. Epub 2018 Mar 8.

PMID:
29526248
15.

Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice.

Grippo PJ, Fitchev PS, Bentrem DJ, Melstrom LG, Dangi-Garimella S, Krantz SB, Heiferman MJ, Chung C, Adrian K, Cornwell ML, Flesche JB, Rao SM, Talamonti MS, Munshi HG, Crawford SE.

Gut. 2012 Oct;61(10):1454-64. doi: 10.1136/gutjnl-2011-300821. Epub 2012 Jan 10.

PMID:
22234980
16.

Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice.

Jandaghi P, Najafabadi HS, Bauer AS, Papadakis AI, Fassan M, Hall A, Monast A, von Knebel Doeberitz M, Neoptolemos JP, Costello E, Greenhalf W, Scarpa A, Sipos B, Auld D, Lathrop M, Park M, Büchler MW, Strobel O, Hackert T, Giese NA, Zogopoulos G, Sangwan V, Huang S, Riazalhosseini Y, Hoheisel JD.

Gastroenterology. 2016 Dec;151(6):1218-1231. doi: 10.1053/j.gastro.2016.08.040. Epub 2016 Aug 28.

PMID:
27578530
17.

A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression.

Wang WY, Hsu CC, Wang TY, Li CR, Hou YC, Chu JM, Lee CT, Liu MS, Su JJ, Jian KY, Huang SS, Jiang SS, Shan YS, Lin PW, Shen YY, Lee MT, Chan TS, Chang CC, Chen CH, Chang IS, Lee YL, Chen LT, Tsai KK.

Gastroenterology. 2013 Nov;145(5):1110-20. doi: 10.1053/j.gastro.2013.07.040. Epub 2013 Jul 27.

PMID:
23896173
18.

Inhibiting YAP expression suppresses pancreatic cancer progression by disrupting tumor-stromal interactions.

Jiang Z, Zhou C, Cheng L, Yan B, Chen K, Chen X, Zong L, Lei J, Duan W, Xu Q, Li X, Wang Z, Ma Q, Ma J.

J Exp Clin Cancer Res. 2018 Mar 27;37(1):69. doi: 10.1186/s13046-018-0740-4.

19.

MicroRNAs of the mir-17~92 cluster regulate multiple aspects of pancreatic tumor development and progression.

Quattrochi B, Gulvady A, Driscoll DR, Sano M, Klimstra DS, Turner CE, Lewis BC.

Oncotarget. 2017 May 30;8(22):35902-35918. doi: 10.18632/oncotarget.16277.

20.

TADG-12 as an early marker in the development of pancreatic ductal adenocarcinoma (PDAC): involvement of insulin containing cells.

Amsterdam A, Raanan C, Shpigner L, Shwiqi A, Melzer E, Schreiber L.

Acta Histochem. 2014 Jun;116(5):781-7. doi: 10.1016/j.acthis.2014.01.007. Epub 2014 Feb 21.

PMID:
24560937

Supplemental Content

Support Center